GM1 Gangliosidosis: Mechanisms and Management

References

• Caciotti A, Garman SC, Rivera-Colón Y, et al. GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochim Biophys Acta - Mol Basis Dis. 2011;1812(7):782–790. doi:10.1016/j.bbadis.2011.03.018
   Web of Science ®Google Scholar
• Jarnes Utz JR, Kim S, King K, et al. Infantile gangliosidoses: mapping a timeline of clinical changes. Mol Genet Metab. 2017;121(2):170–179. doi:10.1016/j.ymgme.2017.04.011
   Web of Science ®Google Scholar
• Regier DS, Kwon HJ, Johnston J, et al. MRI/MRS as a surrogate marker for clinical progression in GM1 gangliosidosis. Am J Med Genet Part A. 2016;170(3):634–644. doi:10.1002/ajmg.a.37468
   Web of Science ®Google Scholar
• Brunetti-Pierri N, Scaglia F. GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab. 2008;391–396. doi:10.1016/j.ymgme.2008.04.012
   Web of Science ®Google Scholar
• Lenicker HM, Agius PV, Young EP, Montalto SPA. Infantile generalized GM1 gangliosidosis: high incidence in the Maltese Islands. J Inherit Metab Dis. 1997;20(5):723–724. doi:10.1023/A:1005303332529
   Web of Science ®Google Scholar
• Sinigerska I, Chandler D, Vaghjiani V, et al. Founder mutation causing infantile GM1-gangliosidosis in the Gypsy population. Mol Genet Metab. 2006;88(1):93–95. doi:10.1016/j.ymgme.2005.12.009
   Web of Science ®Google Scholar
• Nishimoto J, Nanba E, Inui K, Okada S, Suzuki K. GM1-gangliosidosis (genetic β-galactosidase deficiency): identification of four mutations in different clinical phenotypes among Japanese patients. Am J Hum Genet. 1991;49(3):566–574.
   Web of Science ®Google Scholar
• Yoshida K, Oshima A, Sakuraba H, et al. GM1 gangliosidosis in adults: clinical and molecular analysis of 16 Japanese patients. Ann Neurol. 1992;31(3):328–332. doi:10.1002/ana.410310316
   Web of Science ®Google Scholar
• Georgiou T, Stylianidou G, Anastasiadou V, et al. The Arg482His mutation in the β-galactosidase gene is responsible for a high frequency of GM1 gangliosidosis carriers in a Cypriot village. Genet Test. 2005;9(2):126–132. doi:10.1089/gte.2005.9.126
   Google Scholar
• Callahan JW. Molecular basis of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal β-galactosidase and the non-lysosomal β-galactosidase-like protein. Biochim Biophys Acta - Mol Basis Dis. 1999;1455(2–3):85–103. doi:10.1016/S0925-4439(99)00075-7
   PubMed Web of Science ®Google Scholar
• Lawrence R, Van Vleet JL, Mangini L, et al. Characterization of glycan substrates accumulating in GM1 Gangliosidosis. Mol Genet Metab Reports. 2019;21(November):100524. doi:10.1016/j.ymgmr.2019.100524
   Web of Science ®Google Scholar
• Ohto U, Usui K, Ochi T, Yuki K, Satow Y, Shimizu T. Crystal structure of human β-galactosidase: structural basis of G M1 gangliosidosis and morquio B diseases. J Biol Chem. 2012;287(3):1801–1812. doi:10.1074/jbc.M111.293795
   Web of Science ®Google Scholar
• Inui K, Namba R, Ihara Y, et al. A case of chronic GM1 gangliosidosis presenting as dystonia: clinical and biochemical studies. J Neurol. 1990;237(8):491–493. doi:10.1007/bf00314770
   Web of Science ®Google Scholar
• Farrell DF, Ochs U. GM1 Gangliosidosis: phenotypic variation in a single family. Ann Neurol. 1981;9(3):225–231. doi:10.1002/ana.410090304
   Web of Science ®Google Scholar
• Yamamoto A. Localized ß-Galactosidase Deficiency. Arch Intern Med. 1974;134(4):627. doi:10.1001/archinte.1974.00320220029002
   PubMedGoogle Scholar
• Uyama E, Terasaki T, Watanabe S, et al. Type 3 GM1 gangliosidosis: characteristic MRI findings correlated with dystonia. Acta Neurol Scand. 1992;86(6):609–615. doi:10.1111/j.1600-0404.1992.tb05497.x
   Web of Science ®Google Scholar
• Ferreira CR, Gahl WA. Lysosomal storage diseases. Transl Sci Rare Dis. 2017. doi:10.3233/TRD-160005
   Google Scholar
• Tonin R, Caciotti A, Procopio E, et al. Pre-diagnosing and managing patients with GM1 gangliosidosis and related disorders by the evaluation of GM1 ganglioside content. Sci Rep. 2019;9:17684. doi:10.1038/s41598-019-53995-5
   Web of Science ®Google Scholar
• Pierson TM, Adams DA, Markello T, et al. Exome sequencing as a diagnostic tool in a case of undiagnosed juvenile-onset GM 1 -gangliosidosis. Neurology. 2012;79(2):123–126. doi:10.1212/WNL.0b013e31825f047a
   Web of Science ®Google Scholar
• Reuser AJ, Verheijen FW, Bali D, et al. The use of dried blood spot samples in the diagnosis of lysosomal storage disorders - Current status and perspectives. Mol Genet Metab. 2011;104:144–148. doi:10.1016/j.ymgme.2011.07.014
   PubMed Web of Science ®Google Scholar
• Emery JM, Green WR, Wyllie RG, Howell RR. GM1-gangliosidosis: ocular and pathological manifestations. Arch Ophthalmol. 1971;85(2):177–187. doi:10.1001/archopht.1971.00990050179011
   Google Scholar
• Utz JRJ, Crutcher T, Schneider J, Sorgen P, Whitley CB. Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses. Mol Genet Metab. 2015;114(2):274–280. doi:10.1016/j.ymgme.2014.11.015
   Web of Science ®Google Scholar
• Pinsky L, Powell E, Callahan J. GM1-gangliosidosis types 1 and 2: enzymatic differences in cultured fibroblasts. Nature. 1970;228:1093–1095. doi:10.1038/2281093b0
   Web of Science ®Google Scholar
• Van der Voorn JP, Kamphorst W, van der Knaap MS, Powers JM. The leukoencephalopathy of infantile GM1 gangliosidosis: oligodendrocytic loss and axonal dysfunction. Acta Neuropathol. 2004;107(6):539–545. doi:10.1007/s00401-004-0848-9
   PubMed Web of Science ®Google Scholar
• Erol I, Alehan F, Ali Pourbagher M, Canan O, Vefa Yildirim S. Neuroimaging findings in infantile GM1 gangliosidosis. Eur J Paediatr Neurol. 2006;10(5–6):245–248. doi:10.1016/j.ejpn.2006.08.005
   Web of Science ®Google Scholar
• Kaback MM, Sloan HR, Sonneborn M, Herndon RM, Percy AK. Gm1-gangliosidosis type I: in utero detection and fetal manifestations. J Pediatr. 1973;82(6):1037–1041. doi:10.1016/S0022-3476(73)80438-X
   Web of Science ®Google Scholar
• Nestrasil I, Ahmed A, Utz JM, Rudser K, Whitley CB, Jarnes-Utz JR. Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: volumetric quantitative MRI study. Mol Genet Metab. 2018;123(2):97–104. doi:10.1016/j.ymgme.2017.12.432
   Web of Science ®Google Scholar
• Goebel HH, Fix JD, Zeman W. Retinal pathology in GM1 ganglios1dosis, type II. Am J Ophthalmol. 1973;75(3):434–441. doi:10.1016/0002-9394(73)91152-5
   Web of Science ®Google Scholar
• Vieira JP, Conceição C, Scortenschi E. GM1 gangliosidosis, late infantile onset dystonia, and T2 hypointensity in the globus pallidus and substantia nigra. Pediatr Neurol. 2013;49(3):195–197. doi:10.1016/j.pediatrneurol.2013.02.003
   Web of Science ®Google Scholar
• Deodato F, Procopio E, Rampazzo A, et al. The treatment of juvenile/adult GM1-gangliosidosis with Miglustat may reverse disease progression. Metab Brain Dis. 2017;32(5):1529–1536. doi:10.1007/s11011-017-0044-y
   Web of Science ®Google Scholar
• De Grandis E, Di M, Pessagno RA, Veneselli E, Rossi A. MR Imaging Findings in 2 Cases of Late Infantile GM1 Gangliosidosis. AJNR Am J Neuroradiol. 2009;30:1325–1327. doi:10.3174/ajnr.A1508
   Web of Science ®Google Scholar
• Tanaka R, Momoi T, Yoshida A, et al. Type 3 GM I gangliosidosis: clinical and neuroradiological findings in an 11-year-old girl. J Neurol. 1995;242(5):299–303. doi:10.1007/BF00878872
   Web of Science ®Google Scholar
• Roze E, Paschke E, Lopez N, et al. Dystonia and Parkinsonism in GM1 type 3 gangliosidosis. Mov Disord. 2005;20(10):1366–1369. doi:10.1002/mds.20593
   Web of Science ®Google Scholar
• Roze E, Navarro S, Cornu P, Welter ML, Vidailhet M. Deep brain stimulation of the globus pallidus for generalized dystonia in GM1 type 3 gangliosidosis: technical case report. Neurosurgery. 2006;59(6):E1340. doi:10.1227/01.NEU.0000245620.24603.1B
   Web of Science ®Google Scholar
• Kobayashi T, Chronic SK. GM1 gangliosidosis presenting as Dystonia: II. Biochemical studies. Ann Neurol. 1980;9(5):476–483. doi:10.1002/ana.410090510
   Web of Science ®Google Scholar
• Patterson MC. Pediatric Neurology Part III - Gangliosidoses. In: Handbook of Clinical Neurology. Vol. 113. Elsevier;2013:1707–1708. doi:10.1016/B978-0-444-59565-2.00039-3
   Google Scholar
• Hofer D, Paul K, Fantur K, et al. Phenotype determining alleles in GM1 gangliosidosis patients bearing novel GLB1 mutations. Clin Genet. 2010;78(3):236–246. doi:10.1111/j.1399-0004.2010.01379.x
   Web of Science ®Google Scholar
• Brezina PR, Benner A, Rechitsky S, et al. Single-gene testing combined with single nucleotide polymorphism microarray preimplantation genetic diagnosis for aneuploidy: a novel approach in optimizing pregnancy outcome. Fertil Steril. 2011;95:1786.e5-1786.e8. doi:10.1016/j.fertnstert.2010.11.025
   Web of Science ®Google Scholar
• Gillan JE, Lowden JA, Gaskin K, Cutz E. Congenital ascites as a presenting sign of lysosomal storage disease. J Pediatr. 1984;104(2):225–231. doi:10.1016/S0022-3476(84)80997-X
   Web of Science ®Google Scholar
• Lowden JA, Cutz E, Conen PE, Rudd N, Doran TA. Prenatal Diagnosis of GM1-Gangliosidosis. N Engl J Med. 1973;288(5):225–228. doi:10.1056/NEJM197302012880502
   Web of Science ®Google Scholar
• Warner TG, Robertson AD, Mock AK, Johnson WG, O’Brien JS. Prenatal diagnosis of GM1 gangliosidosis by detection of galactosyl-oligosaccharides in amniotic fluid with high-performance liquid chromatography. Am J Hum Genet. 1983;35:1034–1041.
   Web of Science ®Google Scholar
• Chamoles NA, Blanco MB, Iorcansky S, Gaggioli D, Spècola N, Casentini C. Retrospective diagnosis of GM1 gangliosidosis by use of a newborn-screening card. Clin Chem. 2001;47(11):2068. doi:10.1093/clinchem/47.11.2068
   Web of Science ®Google Scholar
• Polo G, Burlina AP, Ranieri E, et al. Plasma and dried blood spot lysosphingolipids for the diagnosis of different sphingolipidoses: A comparative study. Clin Chem Lab Med. 2019;57(12):1863–1874. doi:10.1515/cclm-2018-1301
   Web of Science ®Google Scholar
• Walkley SU, Zervas M, Wiseman S. Gangliosides as modulators of dendritogenesis in normal and storage disease-affected pyramidal neurons. Cereb Cortex. 2000;10(10):1028–1037. doi:10.1093/cercor/10.10.1028
   Web of Science ®Google Scholar
• Walkley SU. Neurobiology and cellular pathogenesis of glycolipid storage diseases. Philos Trans R Soc. 2003;358:893–904. doi:10.1098/rstb.2003.1276
   PubMed Web of Science ®Google Scholar
• Baker HJ, Lindsey JR. Animal model: feline GM1 gangliosidosis. Am J Pathol. 1974;74(3):649–652.
   Web of Science ®Google Scholar
• Baker HJ, Reynolds GD, Walkley SU, Cox NR, Baker GH. The gangliosidoses: comparative features and research applications. Vet Pathol. 1979;16(6):635–649. doi:10.1177/030098587901600602
   Web of Science ®Google Scholar
• Gurda BL, Vite CH. Large animal models contribute to the development of therapies for central and peripheral nervous system dysfunction in patients with lysosomal storage diseases. Hum Mol Genet. 2019;28(R1):R119–R131. doi:10.1093/hmg/ddz127
   Web of Science ®Google Scholar
• Murnane RD, Prieur DJ, Ahern‐Rindell AJ, Holler LD, Parish SM. Clinical and clinicopathologic characteristics of ovine GM‐1 gangliosidosis. J Vet Intern Med. 1994;8(3):221–223. doi:10.1111/j.1939-1676.1994.tb03220.x
   Web of Science ®Google Scholar
• Matsuda J, Suzuki O, Oshima A, et al. Beta-Galactosidase-Deficient Mouse as an Animal Model for GM1-Gangliosidosis. Glycoconj J. 1997;14(6):729–736.
   Google Scholar
• Itoh M, Matsuda J, Suzuki O, et al. Development of lysosomal storage in mice with targeted disruption of the β-galactosidase gene: a model of human GM1-gangliosidosis. Brain Dev. 2001;23(6):379–384. doi:10.1016/S0387-7604(01)00244-3
   Web of Science ®Google Scholar
• Hahn CN, Del Pilar Martin M, Schröder M, et al. Generalized CNS disease and massive G(M1)-ganglioside accumulation in mice defective in lysosomal acid β-galactosidase. Hum Mol Genet. 1997;6(2):205–211. doi:10.1093/hmg/6.2.205
   Web of Science ®Google Scholar
• Eikelberg D, Lehmbecker A, Brogden G, et al. Axonopathy and reduction of membrane resistance: key features in a new murine model of human GM1-gangliosidosis. J Clin Med. 2020;9(4):1004. doi:10.3390/jcm9041004
   Web of Science ®Google Scholar
• Przybilla MJ, Ou L, Tăbăran AF, et al. Comprehensive behavioral and biochemical outcomes of novel murine models of GM1-gangliosidosis and Morquio syndrome type B. Mol Genet Metab. 2019;126(2):139–150. doi:10.1016/j.ymgme.2018.11.002
   Web of Science ®Google Scholar
• Matsuda J, Suzuki O, Oshima A, et al. Chemical chaperone therapy for brain pathology in GM1-Gangliosidosis.Proc Natl Acad Sci U S A. 2003;100(26):15912–7. doi:10.1073/pnas.2536657100.
   Google Scholar
• Reynolds GD, Baker HJ, Reynolds RH. Enzyme replacement using liposome carriers in feline GM1 gangliosidosis fibroblasts. Nature. 1978;275(5682):754–755. doi:10.1038/275754a0
   Web of Science ®Google Scholar
• McCurdy VJ, Johnson AK, Gray-Edwards HL, et al. Sustained normalization of neurological disease after intracranial gene therapy in a feline model. Sci Transl Med. 2014;6(231):231ra48. doi:10.1126/scitranslmed.3007733
   Web of Science ®Google Scholar
• Gray-Edwards HL, Salibi N, Josephson EM, et al. High resolution MRI anatomy of the cat brain at 3 Tesla. J Neurosci Methods. 2014;227:10–17. doi:10.1016/j.jneumeth.2014.01.035
   Web of Science ®Google Scholar
• Gray-Edwards HL, Jiang X, Randle AN, et al. Lipidomic evaluation of feline neurologic disease after AAV gene therapy. Mol Ther - Methods Clin Dev. 2017;6:135–142. doi:10.1016/j.omtm.2017.07.005
   Web of Science ®Google Scholar
• Gray-Edwards HL, Regier DS, Shirley JL, et al. Novel biomarkers of human GM1 gangliosidosis reflect the clinical efficacy of gene therapy in a feline model. Mol Ther. 2017;25(4):892–903. doi:10.1016/j.ymthe.2017.01.009
   PubMed Web of Science ®Google Scholar
• Broekman MLD, Baek RC, Comer LA, Fernandez JL, Seyfried TN, Sena-Esteves M. Complete correction of enzymatic deficiency and neurochemistry in the GM1-gangliosidosis mouse brain by neonatal adeno-associated virus–mediated gene delivery. Mol Ther. 2007;15(1):30–37. doi:10.1038/sj.mt.6300004
   Web of Science ®Google Scholar
• Broekman MLD, Tierney LA, Benn C, Chawla P, Cha JH, Sena-Esteves M. Mechanisms of distribution of mouse β-galactosidase in the adult GM1-gangliosidosis brain. Gene Ther. 2009;16(2):303–308. doi:10.1038/gt.2008.149
   Web of Science ®Google Scholar
• Baek RC, Boekman MLD, Leroy SG, et al. AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival. PLoS One. 2010;5(10):e13468. doi:10.1371/journal.pone.0013468
   Web of Science ®Google Scholar
• Latour YL, Yoon R, Thomas SE, et al. Human GLB1 knockout cerebral organoids: a model system for testing AAV9-mediated GLB1 gene therapy for reducing GM1 ganglioside storage in GM1 gangliosidosis. Mol Genet Metab Reports. 2019;21(May):100513. doi:10.1016/j.ymgmr.2019.100513
   Web of Science ®Google Scholar
• Chiricozzi E, Lunghi G, Di Biase E, Fazzari M, Sonnino S, Mauri L. GM1 ganglioside is a key factor in maintaining the mammalian neuronal functions avoiding neurodegeneration. Int J Mol Sci. 2020;21(3):868. doi:10.3390/ijms21030868
   Web of Science ®Google Scholar
• Chiricozzi E, Pomè DY, Maggioni M, et al. Role of the GM1 ganglioside oligosaccharide portion in the TrkA-dependent neurite sprouting in neuroblastoma cells. J Neurochem. 2017;143(6):645–659. doi:10.1111/jnc.14146
   Web of Science ®Google Scholar
• Mocchetti I. Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell Mol Life Sci. 2005;62:2283–2294. doi:10.1007/s00018-005-5188-y
   PubMed Web of Science ®Google Scholar
• Head BP, Patel HH, Insel PA. Interaction of membrane/lipid rafts with the cytoskeleton: impact on signaling and function: membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling. Biochim Biophys Acta - Biomembr. 2014;1838(2):532–545. doi:10.1016/J.BBAMEM.2013.07.018
   PubMed Web of Science ®Google Scholar
• Jung J-U, Ko K, Lee D-H, Ko K, Chang K-T, Choo Y-K. The roles of glycosphingolipids in the proliferation and neural differentiation of mouse embryonic stem cells. Exp Mol Med. 2009;41(12):935–945. doi:10.3858/emm.2009.41.12.099
   Web of Science ®Google Scholar
• Kolter T, Proia RL, Sandhoff K. Combinatorial ganglioside biosynthesis. J Biol Chem. 2002;277(29):25859–25862. doi:10.1074/jbc.R200001200
   PubMed Web of Science ®Google Scholar
• Yu RK, Tsai Y-T, Ariga T, Yanagisawa M. Structures, biosynthesis, and functions of gangliosides—An overview. J Oleo Sci. 2011;60(10):537–544. 10.5650/jos.60.537.
   PubMed Web of Science ®Google Scholar
• Posse de Chaves E, Sipione S. Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS Lett. 2010;584(9):1748–1759. doi:10.1016/J.FEBSLET.2009.12.010
   PubMed Web of Science ®Google Scholar
• Kolter T. Ganglioside Biochemistry. Int Sch Res Netw Biochem. 2012;2012:1–36. doi:10.5402/2012/506160
   Google Scholar
• Sano R, Trindade VMT, Tessitore A, et al. GM1-ganglioside degradation and biosynthesis in human and murine GM1-gangliosidosis. Clin Chim Acta. 2005;354(1–2):131–139. doi:10.1016/j.cccn.2004.11.035
   Web of Science ®Google Scholar
• Yu RK, Yanagisawa M, Ariga T. Glycosphingolipid Structures. Compr Glycosci from Chem to Syst Biol. 2007;73–122. doi:10.1016/B978-044451967-2/00003-9
   Google Scholar
• Breiden B, Sandhoff K. Ganglioside Metabolism and Its Inherited Diseases. Methods Mol Biol.2018;1804:97–141 doi:10.1007/978-1-4939-8552-4_5
   Google Scholar
• Sandhoff K, Harzer K. Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis. J Neurosci. 2013;33(25):10195–10208. doi:10.1523/JNEUROSCI.0822-13.2013
   PubMed Web of Science ®Google Scholar
• Yoshihara T, Satake H, Nishie T, et al. Lactosylceramide synthases encoded by B4galt5 and 6 genes are pivotal for neuronal generation and myelin formation in mice. PLoS Genet. 2018;14(8):e1007545. doi:10.1371/journal.pgen.1007545
   Web of Science ®Google Scholar
• Yu RK, Ariga T, Yanagisawa M, Zeng G. Gangliosides in the nervous system: biosynthesis and degradation. Glycoscience. 2008;1671–1695. doi:10.1007/978-3-540-30429-6_41
   Google Scholar
• Tettamanti G, Bassi R, Viani P, Riboni L. Salvage pathways in glycosphingolipid metabolism. Biochimie. 2003;85:423–437. doi:10.1016/S0300-9084(03)00047-6
   PubMed Web of Science ®Google Scholar
• Sena-Esteves M, Camp SM, Alroy J, Breakefield XO, Kaye EM. Correction of acid β-galactosidase deficiency in GM1 gangliosidosis human fibroblasts by retrovirus vector-mediated gene transfer: higher efficiency of release and cross-correction by the murine enzyme. Hum Gene Ther. 2000;11(5):715–727. doi:10.1089/10430340050015617
   Web of Science ®Google Scholar
• Takaura N, Yagi T, Maeda M, et al. Attenuation of ganglioside GM1 accumulation in the brain of GM1 gangliosidosis mice by neonatal intravenous gene transfer. Gene Ther. 2003;10:1487–1493. doi:10.1038/sj.gt.3302033
   Web of Science ®Google Scholar
• Shield JPH, Stone J, Steward CG. Bone marrow transplantation correcting β-galactosidase activity does not influence neurological outcome in juvenile GM1-gangliosidosis. J Inherit Metab Dis. 2005;28(5):797–798. doi:10.1007/s10545-005-0089-7
   Web of Science ®Google Scholar
• Sawada T, Tanaka A, Higaki K, et al. Intracerebral cell transplantation therapy for murine GM1 gangliosidosis. Brain Dev. 2009;31(10):717–724. doi:10.1016/j.braindev.2008.11.004
   Web of Science ®Google Scholar
• Hoogerbrugge PM, Brouwer OF, Bordigoni P, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet. 1995;345(8962):1398–1402. doi:10.1016/S0140-6736(95)92597-X
   Web of Science ®Google Scholar
• Sano R, Tessitore A, Ingrassia A, D’Azzo A. Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology. Blood. 2005;106(7):2259–2268. doi:10.1182/blood-2005-03-1189
   PubMed Web of Science ®Google Scholar
• Condori J, Acosta W, Ayala J, et al. Enzyme replacement for GM1-gangliosidosis: uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase: RTB lectin fusion. Mol Genet Metab. 2016;117(2):199–209. doi:10.1016/j.ymgme.2015.12.002
   Web of Science ®Google Scholar
• Gupta M, Pandey H, Sivakumar S. Intracellular Delivery of β-galactosidase enzyme using arginase-responsive dextran sulfate/Poly- l -arginine capsule for lysosomal storage disorder. ACS Omega. 2017;2:9002–9012. doi:10.1021/acsomega.7b01230
   Web of Science ®Google Scholar
• Kelly JM, Gross AL, Martin DR, Byrne ME. Polyethylene glycol-b-poly(lactic acid) polymersomes as vehicles for enzyme replacement therapy. Nanomedicine. 2017;12(23):2591–2606. doi:10.2217/nnm-2017-0221
   Web of Science ®Google Scholar
• Chen JC, Luu AR, Wise N, et al. Intracerebroventricular enzyme replacement therapy with Beta-Galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice. J Biol Chem. 2019;295(39):13532–13555. doi:10.1074/jbc.RA119.009811
   Web of Science ®Google Scholar
• Suzuki Y, Ichinomiya S, Kurosawa M, et al. Chemical chaperone therapy: clinical effect in murine G M1 -gangliosidosis. Ann Neurol. 2007;62(6):671–675. doi:10.1002/ana.21284
   PubMed Web of Science ®Google Scholar
• Suzuki Y. Chemical chaperone therapy for GM1-gangliosidosis. Cell Mol Life Sci. 2008;65:351–353. doi:10.1007/s00018-008-7470-2
   Web of Science ®Google Scholar
• Higaki K, Li L, Bahrudin U, et al. Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in β-galactosidase deficiency. Hum Mutat. 2011;32(7):843–852. doi:10.1002/humu.21516
   Web of Science ®Google Scholar
• Suzuki Y, Ichinomiya S, Kurosawa M, et al. Therapeutic chaperone effect of N-Octyl 4-Epi-β-valienamine on murine GM1-gangliosidosis. Mol Genet Metab. 2012;106:92–98. doi:10.1016/j.ymgme.2012.02.012
   PubMed Web of Science ®Google Scholar
• Rigat BA, Tropak MB, Buttner J, et al. Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy. Mol Genet Metab. 2012;107(1–2):203–212. doi:10.1016/j.ymgme.2012.06.007
   Web of Science ®Google Scholar
• Takamura A, Higaki K, Ninomiya H, et al. Lysosomal accumulation of Trk protein in brain of GM1- gangliosidosis mouse and its restoration by chemical chaperone. J Neurochem. 2011;118:399–406. doi:10.1111/j.1471-4159.2011.07310.x
   PubMed Web of Science ®Google Scholar
• Front S, Biela-Banaś A, Burda P, et al. (5aR)-5a-C-Pentyl-4-epi-isofagomine: a powerful inhibitor of lysosomal β-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B. Eur J Med Chem. 2017;126:160–170. doi:10.1016/j.ejmech.2016.09.095
   Web of Science ®Google Scholar
• Caciotti A, Donati MA, D’Azzo A, et al. The potential action of galactose as a “chemical chaperone”: increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient. Eur J Paediatr Neurol. 2009;13:160–164. doi:10.1016/j.ejpn.2008.03.004
   Web of Science ®Google Scholar
• Coutinho MF, Santos JI, Alves S. Less is more: substrate reduction therapy for lysosomal storage disorders. Int J Mol Sci. 2016;17:7. doi:10.3390/ijms17071065
   Web of Science ®Google Scholar
• Aerts JMFG, Hollak CEM, Boot RG, Groener JEM, Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis. 2006;29:449–456. doi:10.1007/s10545-006-0272-5
   PubMed Web of Science ®Google Scholar
• Elliot-Smith E, Speak AO, Lloyd-Evans E, et al. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. Mol Genet Metab. 2008;94:204–211. doi:10.1016/j.ymgme.2008.02.005
   PubMed Web of Science ®Google Scholar
• Kasperzyk JL, El-Abbadi MM, Hauser EC, D’Azzo A, Platt FM, Seyfried TN. N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. J Neurochem. 2004;89:645–653. doi:10.1046/j.1471-4159.2004.02381.x
   Web of Science ®Google Scholar
• Kwak JE, Son M-Y, Son YS, Son MJ, Cho YS. Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders. Biochem Biophys Res Commun. 2015;457:554–560. doi:10.1016/j.bbrc.2015.01.023
   Web of Science ®Google Scholar
• Galjaard H, Hoogeveen A, Keijzer W, et al. Genetic heterogeneity in GM1-gangliosidosis. Nature. 1975;257:60–62. doi:10.1038/257060a0
   Web of Science ®Google Scholar
• Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062–D1067. doi:10.1093/nar/gkx1153
   PubMed Web of Science ®Google Scholar
• Santamaria R, Chabás A, Coll MJ, Miranda CS, Vilageliu L, Grinberg D. Twenty-one novel mutations in the GLB1 gene identified in a large group of GM1-gangliosidosis and Morquio B patients: possible common origin for the prevalent p.R59H mutation among gypsies. Hum Mutat. 2006;27(10):1060. doi:10.1002/humu.9451
   Google Scholar
• Yoshida K, Oshima A, Shimmoto M, et al. Human beta-galactosidase gene mutations in GM1-gangliosidosis: a common mutation among Japanese adult/chronic cases. Am J Hum Genet. 1991;49(2):435–442.
   Web of Science ®Google Scholar
• Hofer D, Paul K, Fantur K, et al. GM1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid β-galactosidase. Hum Mutat. 2009;30(8):1214–1221. doi:10.1002/humu.21031
   Web of Science ®Google Scholar
• Sperb F, Vairo F, Burin M, Mayer FQ, Matte U, Giugliani R. Genotypic and phenotypic characterization of Brazilian patients with GM1 gangliosidosis. Gene. 2013;512:113–116. doi:10.1016/j.gene.2012.09.106
   Web of Science ®Google Scholar
• Caciotti A, Donati MA, Procopio E, et al. GM1 gangliosidosis: molecular analysis of nine patients and development of an RT-PCR assay for GLB1 gene expression profiling. Hum Mutat. 2007;28(2):204. doi:10.1002/humu.9475
   Web of Science ®Google Scholar
• Morita M, Saito S, Ikeda K, et al. Structural bases of GM1 gangliosidosis and Morquio B disease. J Hum Genet. 2009;54(9):510–515. doi:10.1038/jhg.2009.70
   Web of Science ®Google Scholar
• Caciotti A, Bardelli T, Cunningham J, D’Azzo A, Zammarchi E, Morrone A. Modulating action of the new polymorphism L436F detected in the GLB1 gene of a type-II GM1 gangliosidosis patient. Hum Genet. 2003;113:44–50. doi:10.1007/s00439-003-0930-8
   Web of Science ®Google Scholar
• Tessitore A, Martin MDP, Sano R, et al. GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol Cell. 2004;15(5):753–766. doi:10.1016/j.molcel.2004.08.029
   Web of Science ®Google Scholar
• Martin DR, Rigat BA, Foureman P, et al. Molecular consequences of the pathogenic mutation in feline G M1 gangliosidosis. Mol Genet Metab. 2008;94:212–221. doi:10.1016/j.ymgme.2008.02.004
   Web of Science ®Google Scholar
• Koenig ML, Jope RS, Baker HJ, Lally KM. Reduced Ca2+ flux in synaptosomes from cats with GM1 gangliosidosis. Brain Res. 1987;424(1):169–176. doi:10.1016/0006-8993(87)91207-8
   Web of Science ®Google Scholar
• Spoerri PE, Dozier AK, Roisen FJ. Calcium regulation of neuronal differentiation: the role of calcium in GM1-mediated neuritogenesis. Dev Brain Res. 1990;56:177–188. doi:10.1016/0165-3806(90)90080-I
   PubMedGoogle Scholar
• Wu G, Lu Z‐H, Ledeen RW. GM1 ganglioside in the nuclear membrane modulates nuclear calcium homeostasis during neurite outgrowth. J Neurochem. 1995;65(3):1419–1422. doi:10.1046/j.1471-4159.1995.65031419.x
   Web of Science ®Google Scholar
• Ledeen RW, Wu G. Ganglioside function in calcium homeostasis and signaling. Neurochem Res. 2002;27(7–8):637–647. doi:10.1023/A:1020224016830
   Web of Science ®Google Scholar
• Singer HS, Coyle JT, Weaver DL, Kawamura N, Baker HJ. Neurotransmitter chemistry in feline GM1 gangliosidosis: A model for human ganglioside storage disease. Ann Neurol. 1982;12(1):37–41. doi:10.1002/ana.410120107
   Web of Science ®Google Scholar
• Wood PA, McBride MR, Baker HJ, Christian ST. Fluorescence Polarization Analysis, Lipid Composition, and Na+, K+‐ATPase Kinetics of Synaptosomal Membranes in Feline GM1 and GM2 Gangliosidosis. J Neurochem. 1985;44:947–956. doi:10.1111/j.1471-4159.1985.tb12909.x
   Web of Science ®Google Scholar
• Karabelas AB, Walkley SU. Altered patterns of evoked synaptic activity in cortical pyramidal neurons in feline ganglioside storage disease. Brain Res. 1985;339:329–336. doi:10.1016/0006-8993(85)90099-X
   Web of Science ®Google Scholar
• Walkley SU, Wurzelmann S. Alterations in synaptic connectivity in cerebral cortex in neuronal storage disorders. Ment Retard Dev Disabil Res Rev. 1995;1:183–192. doi:10.1002/mrdd.1410010306
   Google Scholar
• Takamura A, Higaki K, Kajimaki K, et al. Enhanced autophagy and mitochondrial aberrations in murine GM1-gangliosidosis. Biochem Biophys Res Commun. 2008;367:616–622. doi:10.1016/j.bbrc.2007.12.187
   PubMed Web of Science ®Google Scholar
• Jeyakumar M, Thomas R, Elliot-Smith E, et al. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain. 2003;126:974–987. doi:10.1093/brain/awg089
   PubMed Web of Science ®Google Scholar
• Son MY, Kwak JE, Seol B, Lee DY, Jeon H, Cho YS. A novel human model of the neurodegenerative disease GM1 gangliosidosis using induced pluripotent stem cells demonstrates inflammasome activation. J Pathol. 2015;237(1):98–110. doi:10.1002/path.4551
   Web of Science ®Google Scholar
• Folkerth RD, Alroy J, Bhan I, Kaye EM. Infantile G(M1) gangliosidosis: complete morphology and histochemistry of two autopsy cases, with particular reference to delayed central nervous system myelination. Pediatr Dev Pathol. 2000;3:73–86. doi:10.1007/s100240050010
   Web of Science ®Google Scholar
• Suzuki K. Neuropathology of late onset gangliosidoses. Dev Neurosci. 1991;13:205–210. doi:10.1159/000112161
   Web of Science ®Google Scholar
• Van der Voorn JP, Pouwels PJW, Kamphorst W, et al., Histopathologic correlates of radial stripes on MR images in lysosomal storage disorders. Am J Neuroradiol. 2005;26:442–446.
   PubMed Web of Science ®Google Scholar
• Müller G, Alldinger S, Moritz A, et al. GM1-gangliosidosis in Alaskan huskies: clinical and pathologic findings. Vet Pathol. 2001;38:281–290. doi:10.1354/vp.38-3-281
   Web of Science ®Google Scholar
• Read DH, Harrington DD, Keenan TW, Hinsman EJ. Neuronal-Visceral GM1 Gangliosidosis in a dog with beta-galactosidase deficiency. Science. 1976;194:442–445.
   Web of Science ®Google Scholar
• Hanna RB, Pappas GD, Purpura DP. Freeze-fracture study of membranous cytoplasmic bodies of cortical neurons in feline GM1-ganglioside storage disease. Brain Res. 1982;252:172–176. doi:10.1016/0006-8993(82)90993-3
   Web of Science ®Google Scholar
• Walkley SU, Baker HJ, Rattazzi MC, Haskins ME, Wu JY. Neuroaxonal dystrophy in neuronal storage disorders: evidence for major GABAergic neuron involvement. J Neurol Sci. 1991;104:1–8. doi:10.1016/0022-510X(91)90208-O
   Web of Science ®Google Scholar
• Novikoff AB. Lysosomes: A personal Account. In: Lysosomes and Storage Diseases. 1973:1–41.
   Google Scholar
• Read DH, Harrington DD, Keenan TW, Hinsman EJ. Neuronal-Visceral GM1 gangliosidosis in a dog with beta-galactosidase deficiency. Science. 1976;194(4263):442–445.
   Web of Science ®Google Scholar
• Müller G, Alldinger S, Moritz A, et al. GM1-gangliosidosis in Alaskan huskies: clinical and pathologic findings. Vet Pathol. 2001;38(3):281–290. doi:10.1354/vp.38-3-281
   Web of Science ®Google Scholar
• Purpura DP, Pappas GD, Baker HJ. Fine structure of meganeurites and secondary growth processes in feline GM1-gangliosidosis. Brain Res. 1978;143:1–12. doi:10.1016/0006-8993(78)90748-5
   Web of Science ®Google Scholar
• Walkley SU. Cellular pathology of lysosomal storage disorders. Brain Pathol. 1998;8:175–193. doi:10.1111/j.1750-3639.1998.tb00144.x
   PubMed Web of Science ®Google Scholar
• Walkley SU, Wurzelmann S, Purpura DP. Ultrastructure of neurites and meganeurites of cortical pyramidal neurons in feline gangliosidosis as revealed by the combined Golgi-EM technique. Brain Res. 1981;211:393–398. doi:10.1016/0006-8993(81)90711-3
   Web of Science ®Google Scholar
• Bahr BA, Bendiske J. The neuropathogenic contributions of lysosomal dysfunction. J Neurochem. 2002;83:481–489. doi:10.1046/j.1471-4159.2002.01192.x
   PubMed Web of Science ®Google Scholar
• Pará C, Bose P, Pshezhetsky AV. Neuropathophysiology of lysosomal storage diseases: synaptic dysfunction as a starting point for disease progression. J Clin Med. 2020;9:616. doi:10.3390/jcm9030616
   Web of Science ®Google Scholar
• Muthane U, Chickabasaviah Y, Kaneski C, et al. Clinical features of adult G M1 gangliosidosis: report of three Indian patients and review of 40 cases. Mov Disord. 2004;19(11):1334–1341. doi:10.1002/mds.20193
   Web of Science ®Google Scholar
• Goldman JE, Katz D, Rapin I, Purpura DP, Suzuki K. Chronic GM1 gangliosidosis presenting as dystonia: I. Clinical and pathological features. Ann Neurol. 1981;9(5):465–475. doi:10.1002/ana.410090509
   Web of Science ®Google Scholar
• Wenger DA, Sattler M, Mueller OT, Myers GG, Schneiman RS, Nixon GW. Adult GM1 gangliosidosis: clinical and biochemical studies on two patients and comparison to other patients called variant or adult Gm1 gangliosidosis. Clin Genet. 1980;17:323–334. doi:10.1111/j.1399-0004.1980.tb00158.x
   Web of Science ®Google Scholar
• Kaye EM, Alroy J, Raghavan SS, et al. Dysmyelinogenesis in animal model of GM1 gangliosidosis. Pediatr Neurol. 1992;8(4):255–261. doi:10.1016/0887-8994(92)90361-2
   Web of Science ®Google Scholar
• Heinecke KA, Luoma A, D’Azzo A, Kirschner DA, Seyfried TN. Myelin abnormalities in the optic and sciatic nerves in mice with GM1-gangliosidosis. ASN Neuro. 2015;7:1–15. doi:10.1177/1759091415568913
   Web of Science ®Google Scholar
• Gray-Edwards HL, Maguire AS, Salibi N, et al. 7T MRI predicts amelioration of neurodegeneration in the brain after AAV gene therapy. Mol Ther - Methods Clin Dev. 2020;17:258–270. doi:10.1016/j.omtm.2019.11.023
   Web of Science ®Google Scholar
• M-B C-G, Wang SZ, Ziegler R, Cheng SH, Cox TM. Reversibility of neuropathology in Tay-Sachs-related diseases. Hum Mol Genet. 2014;23:730–748. doi:10.1093/hmg/ddt459
   Web of Science ®Google Scholar
• Buccinnà B, Piccinini M, Prinetti A, et al. Alterations of myelin-specific proteins and sphingolipids characterize the brains of acid sphingomyelinase-deficient mice, an animal model of Niemann-Pick disease type A. J Neurochem. 2009;109:105–115. doi:10.1111/j.1471-4159.2009.05947.x
   PubMed Web of Science ®Google Scholar
• Yan X, Lukas J, Witt M, et al. Decreased expression of myelin gene regulatory factor in Niemann-Pick type C 1 mouse. Metab Brain Dis. 2011;26(4):299–306. doi:10.1007/s11011-011-9263-9
   Web of Science ®Google Scholar
• Svennerholm L, Vanier MT, Mansson JE. Krabbe disease: a galactosylsphingosine (psychosine) lipidosis. J Lipid Res. 1980;21(1):53–64. doi:10.1016/S0022-2275(20)39839-4
   PubMed Web of Science ®Google Scholar
• Yamato O, Masuoka Y, Yonemura M, et al. Clinical and clinico-pathologic characteristics of Shiba dogs with a deficiency of lysosomal acid β-galactosidase: a canine model of human GM1 gangliosidosis. J Vet Med Sci. 2003;65(2):213–217. doi:10.1292/jvms.65.213
   Web of Science ®Google Scholar
• Moore GJ. Proton magnetic resonance spectroscopy in pediatric neuroradiology. Pediatr Radiol. 1998;28(11):805–814. doi:10.1007/s002470050470
   Web of Science ®Google Scholar
• Satoh H, Yamato O, Asano T, et al. Cerebrospinal fluid biomarkers showing neurodegeneration in dogs with GM1 gangliosidosis: possible use for assessment of a therapeutic regimen. Brain Res. 2007;1133:200–208. doi:10.1016/j.brainres.2006.11.039
   Web of Science ®Google Scholar
• Brunetti-Pierri N, Bhattacharjee MB, Wang ZJ, et al. Brain proton magnetic resonance spectroscopy and neuromuscular pathology in a patient with GM1 gangliosidosis. J Child Neurol. 2008;23(1):73–78. doi:10.1177/0883073807307088
   Web of Science ®Google Scholar
• Ong MT, Chow GCS, Morton RE. Dual diagnosis of dihydropyrimidine dehydrogenase deficiency and GM 1 gangliosidosis. Pediatr Neurol. 2012;46:178–181. doi:10.1016/j.pediatrneurol.2011.12.005
   Web of Science ®Google Scholar
• Al-Essa MA, Bakheet SM, Patay ZJ, Nounou RM, Ozand PT. Cerebral fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography (FDG PET), MRI, and clinical observations in a patient with infantile G(M1) gangliosidosis. Brain Dev. 1999;21(8):559–562. doi:10.1016/s0387-7604(99)00073-x
   Web of Science ®Google Scholar
• Chen CY, Zimmerman RA, Lee CC, Chen FH, Yuh YS, Hsiao HS. Neuroimaging findings in late infantile GM1 gangliosidosis. Am J Neuroradiol. 1998;19(9):1628–1630. doi:10.3174/ajnr.a1508
   Web of Science ®Google Scholar
• Di Rocco M, Rossi A, Parenti G, et al. Different molecular mechanisms leading to white matter hypomyelination in infantile onset lysosomal disorders. Neuropediatrics. 2005;36(4):265–269. doi:10.1055/s-2005-865863
   Web of Science ®Google Scholar
• Ji H, Li D, Wu Y, et al. Hypomyelinating disorders in China: the clinical and genetic heterogeneity in 119 patients. PLoS One. 2018;13(2):e0188869. doi:10.1371/journal.pone.0188869
   PubMed Web of Science ®Google Scholar
• Kobayashi O, Takashima S. Thalamic hyperdensity on CT in infantile GM1-gangliosidosis. Brain Dev. 1994;16(6):472–474. doi:10.1016/0387-7604(94)90011-6
   Web of Science ®Google Scholar
• Lin HC, Tsai FJ, Shen WC, Tsai CH, Peng CT. Infantile form GM1 gangliosidosis with dilated cardiomyopathy: a case report. Acta Paediatr Int J Paediatr. 2000;89(7):880–883. doi:10.1111/j.1651-2227.2000.tb00398.x
   Web of Science ®Google Scholar
• Hasegawa D, Tamura S, Nakamoto Y, et al. Magnetic resonance findings of the corpus callosum in canine and feline lysosomal storage diseases. PLoS One. 2013;8(12):e83455. doi:10.1371/journal.pone.0083455
   Web of Science ®Google Scholar
• Steenweg ME, Vanderver A, Blaser S, et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain. 2010;133:2971–2982. doi:10.1093/brain/awq257
   PubMed Web of Science ®Google Scholar
• Campdelacreu J, Muñoz E, Gómez B, Pujol T, Chabás A, Tolosa E. Generalised dystonia with an abnormal magnetic resonance imaging signal in the basal ganglia: a case of adult-onset GM1 gangliosidosis. Mov Disord. 2002;17(5):1095–1097. doi:10.1002/mds.10247
   Web of Science ®Google Scholar
• Malik P, Muthusamy K, C M D, Sudhakar SV. Teaching NeuroImages: wishbone pattern of iron accumulation: a characteristic imaging sign in GM1 gangliosidosis. Neurology. 2019;92(18):e2176–e2177. doi:10.1212/WNL.0000000000007406
   Web of Science ®Google Scholar
• Marangi A, Tagliapietra M, Vicenzi V, Pasquin I, Salviati A. Teaching NeuroImages: brain MRI and DaT-SPECT imaging in adult GM1 gangliosidosis. Neurology. 2018;91(2):e187–e188. doi:10.1212/WNL.0000000000005775
   Web of Science ®Google Scholar
• Platt FM, Butters TD. Substrate Reduction Therapy. Editors, John A. Barranger and Mario A. Cabrera-Salazar. In: Lysosomal Storage Disorders. Boston, MA: Springer US;2007:153–168. doi:10.1007/978-0-387-70909-3_11
   Google Scholar
• Kasperzyk JL, D’Azzo A, Platt FM, Alroy J, Seyfried TN. Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice. J Lipid Res. 2005;46:744–751. doi:10.1194/jlr.M400411-JLR200
   PubMed Web of Science ®Google Scholar
• RFG F, Furneaux RH, Mahuran DJ, et al. 1-Deoxy-d-galactonojirimycins with dansyl capped N-substituents as β-galactosidase inhibitors and potential probes for GM1 gangliosidosis affected cell lines. Carbohydr Res. 2011;346(12):1592–1598. doi:10.1016/j.carres.2011.05.010
   Web of Science ®Google Scholar
• Thonhofer M, Gonzalez Santana A, Fischer R, et al. 5-Fluoro derivatives of 4-epi-isofagomine as d-galactosidase inhibitors and potential pharmacological chaperones for GM1-gangliosidosis as well as Fabry’s disease. Carbohydr Res. 2015;420:6–12. doi:10.1016/j.carres.2015.10.009
   Web of Science ®Google Scholar
• Fantur K, Hofer D, Schitter G, et al. DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human GM1-gangliosidosis fibroblasts. Mol Genet Metab. 2010;100(3):262–268. doi:10.1016/j.ymgme.2010.03.019
   Web of Science ®Google Scholar
• Alfonso P, Pampín S, Estrada J, et al. Miglustat (NB-DNJ) works as a chaperone for mutated acid β-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells, Mol Dis. 2005;35(2):268–276. doi:10.1016/j.bcmd.2005.05.007
   PubMed Web of Science ®Google Scholar
• Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994;269(11):8362–8365. doi:10.1016/S0021-9258(17)37202-2
   PubMed Web of Science ®Google Scholar
• Fischer PB, Collin M, Karlsson GB, et al. The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J Virol. 1995;69(9):5791–5797. doi:10.1128/jvi.69.9.5791-5797.1995
   PubMed Web of Science ®Google Scholar
• Jeyakumar M, Butters TD, Cortina-Borja M, et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A. 1999;96(11):6388–6393. doi:10.1073/pnas.96.11.6388
   Web of Science ®Google Scholar
• Jeyakumar M, Dwek RA, Butters TD, Platt FM. Storage solutions: treating lysosomal disorders of the brain. Nat Rev Neurosci. 2005;6(9):713–725. doi:10.1038/nrn1725
   Google Scholar
• Platt FM, Neises GR, Reinkensmeier G, et al. Prevention of lysosomal storage in Tay-Sachs mice treated with N- butyldeoxynojirimycin. Science. 1997;276(5311):428–431. doi:10.1126/science.276.5311.428
   PubMed Web of Science ®Google Scholar
• Higaki K, Ninomiya H, Suzuki Y, Nanba E. Candidate molecules for chemical chaperone therapy of GM1- gangliosidosis. Future Med Chem. 2013;5(13):1551–1558. doi:10.4155/fmc.13.123
   Web of Science ®Google Scholar
• Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med. 2009;1(5):268–279. doi:10.1002/emmm.200900036
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ogawa S, Sakakibara Y. Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. Perspect Medicin Chem. 2009;3:7–19. doi:10.4137/pmc.s2332
   Google Scholar
• Takai T, Higaki K, Aguilar-Moncayo M, et al. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Mol Ther. 2013;21(3):526–532. doi:10.1038/mt.2012.263
   Web of Science ®Google Scholar
• Front S, Almeida S, Zoete V, et al. 4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: improved synthesis and biological investigations. Bioorganic Med Chem. 2018;26(20):5462–5469. doi:10.1016/j.bmc.2018.09.023
   Web of Science ®Google Scholar
• Andersson U, Butters TD, Dwek RA, Platt FM. N-butyldeoxygalactonojirimycin: A more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol. 2000;59(7):821–829. doi:10.1016/S0006-2952(99)00384-6
   PubMed Web of Science ®Google Scholar
• D’Alonzo D, De Fenza M, Porto C, et al. N-Butyl-l-deoxynojirimycin (l-NBDNJ): synthesis of an allosteric enhancer of α-glucosidase activity for the treatment of pompe disease. J Med Chem. 2017;60(23):9462–9469. doi:10.1021/acs.jmedchem.7b00646
   Web of Science ®Google Scholar
• Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of fabry’s disease with galactose-infusion therapy. N Engl J Med. 2001;345:25–32. doi:10.1056/NEJM200107053450104
   PubMed Web of Science ®Google Scholar
• Kuno S, Higaki K, Takahashi A, Nanba E, Ogawa S. Potent chemical chaperone compounds for G M1-gangliosidosis: N-substituted (+)-conduramine F-4 derivatives. Med Chem Commun. 2015;6:306–310. doi:10.1039/c4md00270a
   Google Scholar
• Biffi A, De Palma M, Quattrini A, et al. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J Clin Invest. 2004;113(8):1118–1129. doi:10.1172/jci19205
   PubMed Web of Science ®Google Scholar
• Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341(6148):1233158. doi:10.1126/science.1233158
   PubMed Web of Science ®Google Scholar
• Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, Phase 1/2 trial. Lancet. 2016;388(10043):476–487. doi:10.1016/S0140-6736(16)30374-9
   PubMed Web of Science ®Google Scholar
• Weismann CM, Ferreira J, Keeler AM, et al. Systemic AAV9 gene transfer in adult GM1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespan. Hum Mol Genet. 2015;24(15):4353–4364. doi:10.1093/hmg/ddv168
   Google Scholar
• Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27:59–65. doi:10.1038/nbt.1515
   PubMed Web of Science ®Google Scholar
• Cearley CN, Wolfe JH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther. 2006;13(3):528–537. doi:10.1016/j.ymthe.2005.11.015
   PubMed Web of Science ®Google Scholar